Zilretta
Zilretta Now Available for Osteoarthritis Knee Pain
December 01, 2017Flexion Therapeutics announced the availability of Zilretta (triamcinolone acetonide extended-release injectable suspension) indicated for the management of pain associated with osteoarthritis (OA) of the knee.
FDA Approves Zilretta NDA for Knee Osteoarthritis
February 16, 2017The Food and Drug Administration has accepted for review the New Drug Application for Zilretta for the treatment of patients with osteoarthritis of the knee.
Clinical Pain Advisor Articles
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Hemicrania Continua: Diagnosis and Treatment
- Quantity of Opioids Prescribed Linked to Higher Patient-Reported Consumption
- Ensuring Safety During Long-Term Opioid Therapy
- Drug Overdose Mortality Rates Rising in the United States
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Business Degree Increasingly Useful for Doctors
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Pediatric Opioid Prescriptions Have Declined Since 2012
- Intervention by Pharmacists May Effectively Reduce Use of Inappropriate Medications in the Elderly
- ACA Coverage Substantial, but Did Not Impact Labor Markets
- AMA to Collect Data on Suicide Among Doctors-in-Training
- Smartphone App Improves Management of Cancer-Related Pain, Anxiety
